Join to View Full Profile
Huntsman Cancer Institute2000, Circle of Hope RS2509Salt Lake City, UT 84112
Phone+1 713-231-8086
Dr. Vaklavas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2006 - 2009
Aristotle University of Thessaloniki School of MedicineClass of 2001
Certifications & Licensure
UT State Medical License 2019 - 2026
AL State Medical License 2010 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
- Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Publications & Presentations
PubMed
- Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
JCO Precision Oncology. 2025-04-01 - A compositeF-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
Breast. 2025-03-01 - 11 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
Press Mentions
Well-Designed Phase Ia and Ib Trials Point the Way to New Treatment OptionsMarch 5th, 2025- New Tool Predicts Severity of TNBCSeptember 11th, 2024
- Researchers Develop Mechanism That Predicts Severity of Aggressive Form of Breast CancerSeptember 5th, 2024
- Join now to see all
Grant Support
- A feasibility trial of functional precision cancer medicine to inform treatment selection in metastatic breast cancerUNIVERSITY OF UTAH2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
